Testing at Birth – Update from South Africa | Gayle Sherman

International Workshop on HIV & Pediatrics 2016

Virological response and resistance among HIV-infected children on first-line antiretroviral therapy without routine virological monitoring | Dr. Andrew Prendergast

International Workshop on HIV & Pediatrics 2016

UNICEF Consultation: Countries Implementation of B+ | Chewe Luo, MD, PhD

International Workshop on HIV & Pediatrics 2016

Access to antiretroviral initiation among HIV-infected children aged 0-19 years in the International Epidemiologic Databases to Evaluate AIDS Global Network | Dr. V. Leroy

International Workshop on HIV & Pediatrics 2016

Basic Science of Integrase Inhibitors - Mark Wainberg, MD

Global HIV Clinical Forum 2016

Clinical Case Discussion 1 - Pedro Cahn, MD, PhD

Global HIV Clinical Forum 2016

Resistance Characteristics of Integrase inhibitors - Charles Boucher, MD, PhD

Global HIV Clinical Forum 2016

Integrating Science Into The Clinic: Current and Future Use of Integrase Inhibitors - Anton Pozniak, MD, FRCP

Global HIV Clinical Forum 2016

Only the Best in Botswana - Optimizing the ART Response - Ava Avalos, MD

Global HIV Clinical Forum 2016

Optimizing HIV Therapy in Resource Limited Settings - François Venter, MD, FCP, PhD

Global HIV Clinical Forum 2016

Integrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection - Juan Ambrosioni

Global HIV Clinical Forum 2016

Dolutegravir plus two nucleoside reverse transcriptase inhibitors versus efavirenz plus two nucleoside reverse transcriptase inhibitors as initial antiretroviral therapy for people with HIV: a systematic review - George Rutherford, MD, AM

Global HIV Clinical Forum 2016

Response to Raltegravir based third-line antiretroviral therapy among Ugandan children: A Case series from an urban HIV clinic - Victor Musiime, MBChB, MMED, PhD

Global HIV Clinical Forum 2016

Cross-resistance to integrase strand transfer inhibitors (INSTIs) in 23 multiexperienced Mexican patients failing to raltegravir - Aurelio Orta-Reséndiz, MD, MSc

Global HIV Clinical Forum 2016

Pharmacological Considerations & Clinical Case Discussion - Anna Maria Geretti, MD, PhD, FRCPath

Global HIV Clinical Forum 2016

Future Challenges of HIV treatment - Stefano Vella, MD

Global HIV Clinical Forum 2016

HIV Therapy in Populations with Unique Challenges – Pediatrics - Victor Musiime, MBChB, MMED, PhD

Global HIV Clinical Forum 2016

Pharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women - Dr. Minh Patrick Le

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection (IMPAACT P1110) - Dr. Diana Clarke

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Timing of the postpartum curve in pharmacokinetic studies in pregnancy should not be too early - Angela Colbers, PhD

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Other Viruses: using Wolbachia to interrupt transmission of viral infections such as Dengue, Chikungunya and Zika - Steven Kern, PhD

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Effect of Renal Impairment on Drugs Primarily Eliminated by Metabolism or Biliary Excretion: Review of Data from HCV DAA Drugs and Literature - Dr. Tushar Garimella

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Effect of daclatasvir/asunaprevir/beclabuvir in fixed-dose combination on the pharmacokinetics of CYP450/transporter substrates in healthy subjects- Dr. Tushar Garimella

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

The FDA Perspective on Hepatitis C Drug Resistance - Patrick Harrington, PHD

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016